Compare Icl Group Ltd (ICL) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Invesco Ltd. — how do they compare? Icl Group Ltd trades at $5.3 (market cap $6.94B), while Invesco Ltd. trades at $31.45 (market cap $13.85B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Icl Group Ltd pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| ICL | IVZ | |
|---|---|---|
Market Cap | $6.94B | $13.85B |
Sector | Basic Materials | Financials |
52-Week High | $6.84 | $32.01 |
52-Week Low | $4.80 | $20.67 |
Enterprise Value | $9.58B | $24.01B |
Dividend Yield | 3.86% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.465, up 2.34% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, and revenue is projected to grow to $7.7B in 2026. Recent news highlights strong quarterly results and a senior notes offering. The stock shows a neutral sentiment from oscillators, while analyst consensus is entirely Hold.
The outlook is mixed; earnings beats and operational improvements support upside, but declining net margins and a unanimous Hold rating from analysts suggest limited near-term catalysts. Key risks include raw material cost pressures and foreign exchange volatility, which could impact profitability despite positive cash flow trends.
Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.
The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
